1-3 of 3
Keywords: Gefitinib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report

Available to Purchase
Subject Area:
Further Areas
Omar Fahmy, Marcus Scharpf, Tina Schubert, Susan Feyerabend, Arnulf Stenzl, Christian Schwentner, Falko Fend, Georgios Gakis
Journal: Urologia Internationalis
Urol Int (2016) 97 (4): 485–488.
https://doi.org/10.1159/000441700
Published Online: 11 February 2016
..., but developed pulmonary metastatic disease 7 months postoperatively. Six cycles of gemcitabine/cisplatin combination chemotherapy with an addition of gefitinib as daily oral medication were administered within a randomized phase II clinical trial; this resulted in complete remission of the pulmonary metastases...
View article titled, Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report
Open the PDF for Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report in another window
Journal Articles

A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Available to Purchase
Subject Area:
Further Areas
Kurt Miller, Rudolf Morant, Arnulf Stenzl, Ivan Zuna, Manfred Wirth
Journal: Urologia Internationalis
Urol Int (2016) 96 (1): 5–13.
https://doi.org/10.1159/000381589
Published Online: 06 June 2015
...Kurt Miller; Rudolf Morant; Arnulf Stenzl; Ivan Zuna; Manfred Wirth Introduction: This phase II trial evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in combination with first-line chemotherapy in advanced urothelial cancer...
View article titled, A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Open the PDF for A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in another window
Journal Articles

Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib

Available to Purchase
Subject Area:
Further Areas
Giuseppe Curigliano, Gianluca Spitaleri, Ottavio De Cobelli, Epifanio Scardino, Alberto Sbanotto, Filippo de Braud
Journal: Urologia Internationalis
Urol Int (2009) 82 (2): 196–202.
https://doi.org/10.1159/000200800
Published Online: 19 March 2009
... the impact of gefitinib on QoL of patients with HRPC. Methods: Patients with HRPC received gefitinib 250 mg daily in addition to antiandrogen plus luteinizing hormone-releasing hormone (LHRH) analogue for at least 2 months or until disease progression. QoL was evaluated monthly by the European Organisation...
View article titled, Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib
Open the PDF for Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib in another window